Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MLN-519. Millennium/PAION.

Mario Di Napoli1, Francesca Papa

  • 1Neurological Section, SMDN-Center for Cardiovascular Medicine, 41 Via Trento, I-67039-Sulmona, AQ, Italy. mariodinapoli@katamail.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Adenosine A1/A3 Receptors Agonist on Improving the Outcomes of TBI and Stroke: Focus on AST-004.

Current neurology and neuroscience reports·2026
Same author

Impact of Mandibular Advancement Therapy on Occlusal Plane Orientation and Incisor Inclination in Obstructive Sleep Apnea Patients: A Retrospective Observational Study.

Journal of clinical medicine·2025
Same author

On Neurocardiology Updates: an Interdisciplinary Field at the Intersection of Neurology and Cardiology.

Current neurology and neuroscience reports·2025
Same author

Interleukin-6 and its association with outcome in traumatic brain injury: a prospective cohort.

Scandinavian journal of trauma, resuscitation and emergency medicine·2025
Same author

Traumatic Brain Injury and Gut Microbiome: The Role of the Gut-Brain Axis in Neurodegenerative Processes.

Current neurology and neuroscience reports·2025
Same author

Trends in Ischemic Stroke Hospitalization and Outcomes in the United States Pre- and Peri-COVID-19 Pandemic: A National Inpatient Sample Study.

Journal of clinical medicine·2025

MLN-519, a novel ubiquitin/proteasome inhibitor, is being developed for inflammatory diseases and stroke. Early clinical trials are underway for acute stroke and myocardial infarction treatment.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Clinical Medicine

Background:

  • The ubiquitin/proteasome system plays a critical role in cellular regulation.
  • Dysregulation of this system is implicated in inflammatory diseases and ischemic conditions like stroke.
  • Targeting the ubiquitin/proteasome pathway presents a potential therapeutic strategy.

Purpose of the Study:

  • To investigate the therapeutic potential of MLN-519, a novel ubiquitin/proteasome enzyme inhibitor.
  • To evaluate MLN-519 for the treatment of inflammatory conditions and stroke.
  • To assess the safety and efficacy of MLN-519 in early-phase clinical trials.

Main Methods:

  • Development of MLN-519 by Millennium Pharmaceuticals Inc. and PAION GmbH.
  • Conducting Phase I clinical trials to assess safety and tolerability.

Related Experiment Videos

  • Investigating MLN-519 in preclinical models of inflammatory diseases and stroke.

    • Main Results:

    • MLN-519 is an investigational ubiquitin/proteasome enzyme inhibitor.
    • Phase I clinical trials are currently in progress for acute stroke and myocardial infarction.
    • The drug is progressing towards Phase II clinical trials, indicating promising early-stage results.

    Conclusions:

    • MLN-519 demonstrates potential as a therapeutic agent for inflammatory diseases and stroke.
    • Ongoing clinical trials will further elucidate its efficacy and safety profile.
    • The development of MLN-519 highlights the therapeutic promise of targeting the ubiquitin/proteasome pathway.